相似文献
1
Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.
J Invest Dermatol. 2009 Oct;129(10):2470-9. doi: 10.1038/jid.2009.86. Epub 2009 Apr 9.
2
Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
BMC Microbiol. 2010 Jun 3;10:163. doi: 10.1186/1471-2180-10-163.
3
High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
J Invest Dermatol. 2009 May;129(5):1174-84. doi: 10.1038/jid.2008.349. Epub 2008 Nov 13.
4
[Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs].
Hautarzt. 2010 Dec;61(12):1073-8. doi: 10.1007/s00105-010-2075-8.
5
Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs.
J Invest Dermatol. 2008 Dec;128(12):2825-32. doi: 10.1038/jid.2008.142. Epub 2008 May 22.
6
Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
J Virol. 2011 May;85(10):5036-47. doi: 10.1128/JVI.02548-10. Epub 2011 Mar 9.
7
Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
J Virol. 2015 Jan;89(1):83-96. doi: 10.1128/JVI.02380-14. Epub 2014 Oct 15.
8
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
PLoS One. 2011 Mar 11;6(3):e17748. doi: 10.1371/journal.pone.0017748.
9
Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.
10
Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
J Virol. 2011 Oct;85(20):10472-86. doi: 10.1128/JVI.00849-11. Epub 2011 Aug 3.
引用本文的文献
1
Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.
Curr Clin Microbiol Rep. 2015 Sep 1;2(3):125-136. doi: 10.1007/s40588-015-0020-4. Epub 2015 Jul 1.
2
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
J Virol. 2015 Nov 11;90(1):562-74. doi: 10.1128/JVI.01845-15. Print 2016 Jan 1.
3
A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
PLoS One. 2014 Oct 28;9(10):e109890. doi: 10.1371/journal.pone.0109890. eCollection 2014.
4
A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs.
PLoS One. 2014 Jun 30;9(6):e101373. doi: 10.1371/journal.pone.0101373. eCollection 2014.
5
Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.
Virol J. 2013 Oct 28;10:317. doi: 10.1186/1743-422X-10-317.
6
The challenge of developing a herpes simplex virus 2 vaccine.
Expert Rev Vaccines. 2012 Dec;11(12):1429-40. doi: 10.1586/erv.12.129.
7
Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2.
Front Microbiol. 2012 Apr 30;3:158. doi: 10.3389/fmicb.2012.00158. eCollection 2012.
8
Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
J Virol. 2011 May;85(10):5036-47. doi: 10.1128/JVI.02548-10. Epub 2011 Mar 9.
9
[Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs].
Hautarzt. 2010 Dec;61(12):1073-8. doi: 10.1007/s00105-010-2075-8.
10
HSV Recombinant Vectors for Gene Therapy.
Open Virol J. 2010 Jun 18;4:123-56. doi: 10.2174/1874357901004030123.
本文引用的文献
1
High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
J Invest Dermatol. 2009 May;129(5):1174-84. doi: 10.1038/jid.2008.349. Epub 2008 Nov 13.
2
Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs.
J Invest Dermatol. 2008 Dec;128(12):2825-32. doi: 10.1038/jid.2008.142. Epub 2008 May 22.
3
Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics.
Sex Transm Infect. 2007 Aug;83 Suppl 1:i17-24. doi: 10.1136/sti.2006.023549. Epub 2007 Apr 3.
4
Herpes simplex virus type 2: epidemiology and management options in developing countries.
Sex Transm Infect. 2007 Feb;83(1):16-22. doi: 10.1136/sti.2006.020966. Epub 2006 Nov 10.
5
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.
JAMA. 2006 Aug 23;296(8):964-73. doi: 10.1001/jama.296.8.964.
6
Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study.
J Infect Dis. 2006 Sep 1;194(5):561-70. doi: 10.1086/506455. Epub 2006 Jul 28.
7
Herpes simplex encephalitis: adolescents and adults.
Antiviral Res. 2006 Sep;71(2-3):141-8. doi: 10.1016/j.antiviral.2006.04.002. Epub 2006 Apr 25.
8
Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector.
Mol Ther. 2006 Jun;13(6):1133-41. doi: 10.1016/j.ymthe.2006.01.009. Epub 2006 Mar 29.
9
Replication-defective viruses as vaccines and vaccine vectors.
Virology. 2006 Jan 5;344(1):230-9. doi: 10.1016/j.virol.2005.09.020.
10
Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
J Infect Dis. 2005 Dec 15;192(12):2117-23. doi: 10.1086/498247. Epub 2005 Nov 11.
Zotero 插件